USPTO Examiner OH TAYLOR V - Art Unit 1625

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19268798METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERSJuly 2025September 2025Allow200NoNo
19224580METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROMEMay 2025August 2025Allow310NoNo
19218915APPLICATION OF GENIPIN BETA-METHYL DERIVATIVE GEN-17 IN PREPARATION OF DRUG FOR PREVENTION AND TREATMENT OF ACUTE SEVERE PNEUMONIAMay 2025September 2025Allow310NoNo
19210905METHOD FOR CARBON DIOXIDE FIXATION USING A PALLADIUM-DOPED NITROGEN-RICH ORGANIC FRAMEWORK CATALYSTMay 2025August 2025Allow310NoNo
18988636METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROMEDecember 2024May 2025Allow510NoNo
18978995PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOFDecember 2024April 2025Allow410YesNo
189255432,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA 3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2024June 2025Abandon810NoNo
18895254METHOD FOR PREPARING 5-HYDROXYMETHYLFURFURALSeptember 2024February 2025Allow510NoNo
18824811METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROMESeptember 2024November 2024Allow210YesNo
18795384METHODS FOR TREATING CANCERAugust 2024January 2025Allow510YesNo
18778902METHOD FOR CONTINUOUSLY SYNTHESIZING 5-HYDROXYMETHYLFURFURAL BY USING MICRO-CHANNEL REACTORJuly 2024December 2024Allow510NoNo
18770589METHOD FOR SYNTHESIZING 1,3,2-DIOXATHIOLANE 2,2-DIOXIDE BY IN-SITU CATALYTIC OXIDATIONJuly 2024December 2024Allow510NoNo
187475403-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERSJune 2024July 2025Allow1320NoNo
18742346METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERSJune 2024April 2025Allow1010NoNo
18655452PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDEMay 2024August 2025Allow1610YesNo
18637793COMPOUNDS FOR THE REDUCING LIPOTOXIC DAMAGEApril 2024February 2025Allow1010NoNo
18635657ACETYLSALICYLIC ACID DERIVATIVE AND APPLICATION THEREOFApril 2024August 2025Allow1620YesNo
18633272TARGETED DEGRADATION OF VAV1April 2024August 2024Allow410NoNo
18699960COUPLED UREA MELAMINE PLANTApril 2024February 2025Allow1111NoNo
18586669METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITYFebruary 2024April 2025Abandon1310NoNo
18442393HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSIONFebruary 2024December 2024Allow1010NoNo
18440652METHODS OF ADMINISTERING ANTI-FIBROTIC THERAPYFebruary 2024November 2024Allow910NoNo
184372275-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PENTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDFebruary 2024July 2024Allow510NoNo
18429126[3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDJanuary 2024October 2024Allow820NoNo
18421914METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROMEJanuary 2024July 2024Allow610NoNo
18412805ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASEJanuary 2024January 2025Allow1210NoNo
18392203SELECTIVE LIGANDS FOR MODULATION OF GIRK CHANNELSDecember 2023March 2025Allow1410NoNo
18391421PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOFDecember 2023December 2024Allow1210NoNo
18535256OXYSTEROLS AND METHODS OF USE THEREOFDecember 2023May 2025Allow1710NoNo
185340787-(4-FLUOROBENZYLIDENE)-4-(4-FLUOROPHENYL)-2-METHOXY-6,7-DIHYDRO-5H-CYCLOPENTA[B]PYRIDINE-3-CARBONITRILE AS AN ANTIMICROBIAL COMPOUNDDecember 2023March 2024Allow310NoNo
185336253-CYANO-2-ETHOXY-9-(2-NITROBENZYLIDENE)-4-(2-NITROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRIDINE AS AN ANTIMICROBIAL COMPOUNDDecember 2023April 2024Allow410NoNo
18528910METHOD OF PREPARING AN EXTRACT OF CHAYOTEDecember 2023September 2024Abandon910NoNo
18516604COMPOSITIONS OF TROFINETIDENovember 2023January 2025Allow1410NoNo
18509967METHODS FOR TREATING CANCERNovember 2023May 2024Allow610YesNo
183866849-(2-HYDROXYQUINOLINE-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow410NoNo
183865572-[9-(2-HYDROXYPYRIDIN-3-YL)-1,8-DIOXO-1,2,3,4,5,-6,7,8,9,10-DECAHYDROACRIDIN-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow310NoNo
18386465ETHYL 2-[9-(6-CHLORO-2-HYDROXYQUINOLIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow410NoNo
18558454ADENOSINE A3 RECEPTOR ANTAGONISTS FOR TREATING AGING SKIN AND WOUNDSNovember 2023December 2024Allow1311NoNo
183856289-(2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow310NoNo
18494818COMPOUNDS, COMPOSITIONS, METHODS OF USING, AND METHODS FOR PREPARING COMPOUNDSOctober 2023April 2025Allow1710YesNo
18491538ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCEOctober 2023November 2024Allow1310YesNo
18491598SULFOPEROXYCARBOXYLIC ACIDS, THEIR PREPARATION AND METHODS OF USE AS BLEACHING AND ANTIMICROBIAL AGENTSOctober 2023September 2024Allow1110YesNo
18488871SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERSOctober 2023November 2024Allow1310NoNo
1838108512-BROMO-2,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023February 2024Allow410NoNo
18486783NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASESOctober 2023November 2024Allow1310NoNo
18380018N'-({[(5-PHENYL-1,3,4-OXADIAZOL-2-YL)SULFANYL]ACETYL}OXY)BENZENECARBOXIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023February 2024Allow410NoNo
18378901TREATMENT FOR PARKINSON'S DISEASEOctober 2023December 2024Allow1411YesNo
18379115N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow310NoNo
18376526INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOFOctober 2023October 2025Allow2510NoNo
18371619Topical Composition Containing AntioxidantsSeptember 2023September 2024Allow1210YesNo
18471594CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTIONSeptember 2023January 2025Allow1610NoNo
183709831-CYCLOPROPYL-6-FLUORO-4-OXO-7-(4-((5-OXO-2-PHENYL-4-(QUINOLIN-2-YLMETHYLENE)-4,5-DIHYDRO-1H-IMIDAZOL-1-YL)METHYL)PIPERAZIN-1-YL)-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUNDSeptember 2023February 2024Allow510NoNo
18244913COMPOUNDS FOR TREATING TNBCSeptember 2023January 2025Allow1620NoNo
18243991FOLATE SALTSSeptember 2023November 2024Allow1420NoNo
18462899ERGOLINE ANALOGUESSeptember 2023July 2024Allow1010NoNo
18460012CANNABIS COMPOSITIONSeptember 2023October 2024Allow1410NoNo
18279567PROCESS FOR PREPARING N,N'-BIS(2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)HEXANE-1,6-DIAMINEAugust 2023February 2026Allow3010YesNo
182395281,3-BENZOTHIAZOL-2-YL-N'-(BENZOYLOXY)ETHANIMIDAMIDE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDAugust 2023January 2024Allow510NoNo
18236795TOXIC ALDEHYDE RELATED DISEASES AND TREATMENTAugust 2023June 2024Allow1010NoNo
18451465Pharmaceutical Compositions Comprising Heterocycle Fused Gamma Carboline ProdrugsAugust 2023August 2024Allow1210NoNo
18450586METHODS FOR TREATING CANCERAugust 2023November 2023Allow300NoNo
18450902CATALYST SUPPORTS - COMPOSITION AND PROCESS OF MANUFACTUREAugust 2023November 2024Allow1510NoNo
18264435INDOLE ALKALOID AND PREPARATION METHOD AND USE THEREOFAugust 2023February 2026Allow3110NoNo
18263796PROCESS FOR THE EPOXIDATION OF PROPENEAugust 2023November 2025Allow2800YesNo
18363006METHODS FOR PREVENTING OR TREATING H. PYLORI INFECTIONAugust 2023April 2024Allow820NoNo
18228238NOVEL NANO-SIZED 4-BROMO-2-[(9H-PURIN-6-YLIMINO)-METHYL]-PHENOL IMINE PD(II) COMPLEX FOR SUPERIOR PHARMACEUTICAL APPLICATIONSJuly 2023October 2023Allow310NoNo
18273843Compounds for Disease TreatmentJuly 2023February 2026Allow3110NoNo
18218438RECTAL GEL WITH DATE PALM PHENOLICS AND VANILLIC ACIDJuly 2023October 2023Allow310NoNo
18270743INDOLE COMPOUNDS, AND PREPARATION METHODS, AND USES THEREOFJuly 2023January 2026Allow3110NoNo
18269830CROMOLYN DERIVATIVES AND USES THEREOFJune 2023March 2026Allow3310NoNo
18334668NEAR INFRARED PHOTOCATALYST BASED ON TIO2-COATED GOLD NANOPARTICLESJune 2023June 2024Allow1201YesNo
18256596METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOFJune 2023March 2026Abandon3310NoNo
18326732CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUNDMay 2023June 2024Allow1310NoNo
18039236METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF MICROBIAL INFECTIOUS DISEASES AND ASSOCIATED INFLAMMATORY DISORDERS AND FOR THE TREATMENT AND PROPHYLAXIS OF AGING AND ASSOCIATED DISEASESMay 2023February 2026Allow3320NoNo
18254620PROCESS FOR THE PRODUCTION OF ETHYLENE OXIDEMay 2023December 2025Allow3110YesNo
18254211PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WOUND OR SCAR, COMPRISING BENZBROMARONEMay 2023February 2024Allow810NoNo
18322290METHOD OF TREATMENTMay 2023September 2024Abandon1510NoNo
18322167SOLID FORM OF (-)-AMBROX FORMED BY A BIOCONVERSION OF HOMOFARNESOL IN THE PRESENCE OF A BIOCATALYSTMay 2023May 2024Allow1110NoNo
18038317CANNABINOID DERIVATIVES AND THEIR USE THE TREATMENT OF INFLAMMATION AND/OR PAIN AND/OR OBESITYMay 2023March 2026Abandon3410NoNo
18320060CRYSTALLINE FORMS OF IRAK DEGRADERSMay 2023March 2026Abandon3310NoNo
18035627COMPOSITION FOR PREVENTING OR TREATING TNF-alpha-RELATED DISEASE, COMPRISING HYDROFLUMETHIAZIDE AS ACTIVE INGREDIENTMay 2023December 2025Allow3210NoNo
18251646METHOD FOR PREPARING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID, AND PHARMACEUTICAL COMPOSITION COMPRISING SAMEMay 2023March 2026Abandon3410NoNo
181429733-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUSMay 2023July 2024Abandon1410NoNo
18311266N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORSMay 2023February 2025Allow2110YesNo
18297285CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIESApril 2023December 2024Allow2010YesNo
18131695TRANSTHYRETIN TETRAMER STABILIZING AGENT, AND PREVENTING AGENT OR PROGRESSION SUPPRESSING AGENT FOR TRANSTHYRETIN AMYLOIDOSISApril 2023January 2026Allow3410YesNo
18124071PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORSMarch 2023April 2024Allow1310NoNo
18184364METHODS OF USING 4(1H)-QUINOLONE DERIVATIVESMarch 2023July 2024Allow1610YesNo
18120033N-N-DIMETHYLTRYPTAMINE (DMT) AND DMT ANALOG COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOFMarch 2023April 2024Allow1310YesNo
18178062COMPOUNDS FOR THE REDUCING LIPOTOXIC DAMAGEMarch 2023January 2024Allow1010NoNo
18176048BETA-LACTAMASE INHIBITORS AND USES THEREOFFebruary 2023August 2024Abandon1820NoNo
18113721RECTAL GEL WITH DATE PALM PHENOLICS AND VANILLIC ACIDFebruary 2023August 2023Allow611NoNo
18022767METHOD FOR PRODUCING ETHYLENE OXIDEFebruary 2023December 2025Allow3410NoNo
18169807PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOFFebruary 2023September 2023Allow710NoNo
18041394PURIFICATION OF 2,5-FURANDICARBOXYLIC ACID, DIMETHYL ESTER AND OTHER ESTERIFIED PRODUCTSFebruary 2023January 2026Allow3510NoNo
18020120COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING INFLAMMATORY DISEASE CONTAINING ISOOKANIN OR SALT THEREOF AS ACTIVE INGREDIENTFebruary 2023November 2025Allow3310YesNo
18005001METHOD FOR PREPARING PROPYLENE OXIDE BY MEANS OF DIRECT EPOXIDATION OF PROPYLENEJanuary 2023December 2025Allow3510NoNo
18004806GLUCOCORTICOID-SPARING AGENTJanuary 2023January 2026Allow3710NoNo
18013688INDOLE DERIVATIVE AND APPLICATION THEREOFDecember 2022October 2025Allow3410NoNo
18085622MOLECULE HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETODecember 2022February 2024Abandon1420NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OH, TAYLOR V.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
13
Examiner Affirmed
6
(46.2%)
Examiner Reversed
7
(53.8%)
Reversal Percentile
80.5%
Higher than average

What This Means

With a 53.8% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
118
Allowed After Appeal Filing
46
(39.0%)
Not Allowed After Appeal Filing
72
(61.0%)
Filing Benefit Percentile
64.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 39.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner OH, TAYLOR V - Prosecution Strategy Guide

Executive Summary

Examiner OH, TAYLOR V works in Art Unit 1625 and has examined 1,532 patent applications in our dataset. With an allowance rate of 77.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.

Allowance Patterns

Examiner OH, TAYLOR V's allowance rate of 77.8% places them in the 45% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by OH, TAYLOR V receive 1.89 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by OH, TAYLOR V is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +12.7% benefit to allowance rate for applications examined by OH, TAYLOR V. This interview benefit is in the 49% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 35.1% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 69.9% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 29% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 87.0% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 62.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 58.9% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.1% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.6% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.